IPP Bureau
Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial
By IPP Bureau - November 29, 2023
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Roche expands hepatitis diagnostics portfolio
By IPP Bureau - November 29, 2023
Almost 300 million people globally have chronic hepatitis B
Bayer commits to Veeva Vault CRM and Veeva OpenData globally
By IPP Bureau - November 29, 2023
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
Aster to separate its India and GCC businesses to unlock value
By IPP Bureau - November 29, 2023
Both the India and GCC entities will be operated by separate dedicated management teams
Aurobindo Pharma receives USFDA approval for Darunavir Tablets
By IPP Bureau - November 29, 2023
BrainSpec receives FDA clearance to begin using AI-backed solution for non-invasive brain chemistry measurement
By IPP Bureau - November 28, 2023
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
Fortis Healthcare to divest Fortis Malar Hospital, Chennai to MGM Healthcare
By IPP Bureau - November 28, 2023
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Surgeons at Aster RV Hospitals achieve milestone with removal of 345 gallstones
By IPP Bureau - November 28, 2023
This surgery presented unique challenges, particularly due to the size of the gallbladder and the multitude of stones
GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep
By IPP Bureau - November 28, 2023
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Laurus Labs acquires 87.59% stake in Laurus Bio Private
By IPP Bureau - November 25, 2023
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
DxVx plans to make a license-in agreement of OVM-200
By IPP Bureau - November 25, 2023
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Lupin receives tentative approval from USFDA for Canagliflozin Tablets
By IPP Bureau - November 24, 2023
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Lupin receives approval from USFDA for Bromfenac Ophthalmic Solution
By IPP Bureau - November 24, 2023
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
AstraZeneca Pharma India receives permission to Import formulations of new drug for sale
By IPP Bureau - November 23, 2023
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
